Cascades' CEO Talks 'Reality of the Economy' — The Harder Question Is Whether This Pricing Power Can Compound

The CEO of Cascades Inc. told investors last week that the company is "adjusting our pricing to the reality of the economy" and, for the first time, "getting on pace" rather than trailing behind.

That phrase — "reality of the economy" — sounds like a defense. But from an income-growth perspective, it may be the best thing a packaging company's CEO can say in 2026. Because if inflation is more persistent than the market wants to admit, and structural forces keep prices elevated, the companies that survive are the ones that can pass costs through without losing customers.

That single filter — pricing power — eliminates most of the market. Cascades, a Toronto-listed recycled-paper packaging and tissue manufacturer that has been beaten down for years, just passed a meaningful part of the test. Whether it passes the whole test is the question.

The Q2 beat says margins are back on the right side of the trendline

Cascades reported second-quarter FY2026 results on August 6. Revenue was CAD 1.219 billion, up 8% sequentially and 3% year-over-year. Adjusted EBITDA — earnings before interest, taxes, depreciation, and amortization, the closest proxy to operating cash earnings — rose 19% sequentially to CAD 140 million, with margins expanding to 11.5% from 10.5% in Q1.

Adjusted earnings per share of CAD 0.24 obliterated consensus of CAD 0.065, a 269% beat. The stock jumped 8.6% to CAD 15.50 on the report.

What drove it? Packaging. The segment that accounts for roughly 54% of sales posted EBITDA of CAD 120 million with margins back above 15%, up from 14.4% in Q1. Box shipments grew 5.8% year-over-year on a comparable-asset basis, while the industry grew 2.4%. Cascades is taking share.

Selling prices contributed CAD 7 million to sequential EBITDA growth and CAD 13 million year-over-year. That is not a fluke quarter. The March 2026 price increases — $70 per ton on linerboard and white top, $25 per ton on medium — were fully realized. A $50-per-ton increase announced in June is working through the pipeline. Additional September increases of CAD 110 per ton on linerboard and CAD 140 per ton on medium are expected to materialize in Q4.

Management expects annual run-rate adjusted EBITDA to exceed CAD 600 million in the second half of 2026. That's the kind of operating leverage that makes dividend compounding possible again.

The tissue problem hasn't gone away

Here's where the pricing power test gets partial. Tissue sales were CAD 409 million, up 8% sequentially, but tissue EBITDA was only CAD 35 million — margins at 8.6%. Year-over-year, tissue EBITDA actually declined 8% because logistics and transportation costs ate into volume and pricing gains.

The CEO noted tissue pricing adjustments are "below 9%". That's a telling number. It means Cascades is raising prices on tissue but not by enough to fully offset input inflation. In the Away-from-Home market — commercial restrooms, restaurants, public spaces — buyers are price-sensitive and contracts get rebid. Facility managers don't pay for premium; they pay for the lowest cost per unit.

I don't think Cascades has the absolute pricing power of a Kimberly-Clark or a Georgia-Pacific. But 8.6% margins that are stable rather than collapsing, with volume growth and pricing adjustments working through, suggest the worst of the tissue cycle has passed. The Pryor, Oklahoma facility is ramping — Q2 production was 19% higher than Q3 2025 — and cost reductions from the profitability program should help.

The balance sheet is the real constraint

This is where the story gets harder. Cascades carries CAD 1,879 million in net debt, with a leverage ratio (net debt to trailing four-quarter adjusted EBITDA) of 3.3x. That is above the company's own target range of 2.5 to 3.0x. Interest coverage sits at 4.6x, which is adequate but not comfortable for a company whose business is inherently cyclical.

Total debt is CAD 1.975 billion. The company is prioritizing debt reduction, with capital deployment focused on paydown rather than expansion. Capex guidance is modest — CAD 150 to 175 million for the full year — and asset sales have generated CAD 154 million to date against a CAD 230 million target, though some transactions are taking longer than expected.

The dividend — CAD 0.48 annually, yielding around 3.1% on current prices — carries a payout ratio of roughly 48%. That's well within safety margins. Adjusted free cash flow in Q2 was CAD 47 million, and with H2 EBITDA expected to run above CAD 600 million annually, there is enough cash flow to service debt and support the payout.

But the leverage ratio is the variable that keeps this stock out of favor. Until that number comes down decisively below 3.0x, risk-averse capital won't rally behind it. The good news: if the CAD 600+ million EBITDA run rate materializes, trailing leverage drops mechanically even without additional debt paydown.

Tariffs add a shadow, not a cliff

New U.S. tariffs announced in July 2026 could include rates as high as 50% on certain tissue and packaging products exported to the United States. Management estimates the potential impact at up to 5% of adjusted EBITDA and believes it is manageable through tactical initiatives and pricing.

That's a real risk, worth tracking. But 5% of EBITDA on the total picture isn't a company-killer — it's a headwind that compresses the margin of error. Cascades already announced additional price increases to partially offset this, which brings us back to the core question: can they keep passing costs through?

Why this matters for the income investor

I believe inflation is likely to remain more persistent than the market wants to admit. Deglobalization, energy transition costs, supply-chain constraints, and fiscal pressure all tilt the inflation floor higher. In that regime, companies that raise prices without losing customers are the ones that protect your purchasing power.

Cascades is not a mega-cap with global pricing power. It's a mid-tier, recycled-fiber specialist that competes on sustainability credentials, regional density, and customer stickiness. Its packaging clients — food, beverage, e-commerce — spend tens of millions annually on corrugated boxes and can't easily switch suppliers without retooling their supply chains. That creates real switching costs, a form of moat that doesn't show up on a balance sheet but shows up in stable volume.

The circular-economy model — collecting recyclable fiber and converting it into packaging and tissue — insulates Cascades from the virgin-pulp commodity cycle that hurts competitors like International Paper and Packaging Corporation of America. When plastic-replacement regulations tighten, Cascades' fiber-based alternatives become legally relevant for corporate buyers.

None of this makes Cascades a no-brainer. The debt load is real. Tissue margins are thin. Tariffs are a variable. The stock has been a disappointment for a long time, and investors have reasons to be skeptical.

But from an income and risk/reward perspective, the setup is improving. A 3.1% yield with a 48% payout ratio, EBITDA margins that are expanding rather than compressing, market share gains in packaging, and the capacity to implement four rounds of price increases in less than a year — that's a company earning its way back into the compounding zone.

I don't need the market to fall for this to make sense. The appeal is a real-economy business — packaging and tissue are things the economy cannot function without — that is demonstrating it can raise prices in an inflationary environment while carrying a manageable, declining debt burden. If that run-rate EBITDA of CAD 600+ million holds,leverage drops, the dividend grows, and the stock re-rates.

The equity yield curve sweet spot is moderate yields with strong growth potential. Cascades isn't there yet. But the trajectory — packaging margins back above 15%, pricing working through, share gains in North American box shipments — suggests it's closer than it was six months ago.

The title of this article is deliberate. The CEO's words about the "reality of the economy" are a claim worth stress-testing. The Q2 results suggest the claim is grounded in something real. The balance sheet says the story isn't finished. That's the setup worth watching.

This is not a stock I would treat as a yield shortcut. It belongs in the income-growth sleeve as a recovery play — a real-economy company with improving pricing power, a payout that's safe but not generous, and enough optionality on the EBITDA and leverage front to justify conviction from here.

As always, the concentration level that makes sense depends on your own risk tolerance and understanding of the business. For me, a company that makes boxes no one can stop buying and is finally getting pricing right in an inflationary world deserves a closer look — but the debt has to come down first.